300 related articles for article (PubMed ID: 30738154)
1. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials.
Cheng L; Li YY; Hu W; Bai F; Hao HR; Yu WN; Mao XM
Diabetes Metab; 2019 Oct; 45(5):436-445. PubMed ID: 30738154
[TBL] [Abstract][Full Text] [Related]
2. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
Azharuddin M; Adil M; Ghosh P; Sharma M
Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Ruanpeng D; Ungprasert P; Sangtian J; Harindhanavudhi T
Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28440590
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
6. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
Li X; Li T; Cheng Y; Lu Y; Xue M; Xu L; Liu X; Yu X; Sun B; Chen L
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3170. PubMed ID: 30983141
[TBL] [Abstract][Full Text] [Related]
7. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials.
Rong X; Li X; Gou Q; Liu K; Chen X
Diab Vasc Dis Res; 2020; 17(5):1479164120953625. PubMed ID: 32981346
[TBL] [Abstract][Full Text] [Related]
8. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials.
Qian BB; Chen Q; Li L; Yan CF
Osteoporos Int; 2020 Dec; 31(12):2313-2320. PubMed ID: 32780153
[TBL] [Abstract][Full Text] [Related]
9. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
10. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
Wang H; Yang J; Chen X; Qiu F; Li J
Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
[TBL] [Abstract][Full Text] [Related]
11. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
Huang X; Dannya E; Liu X; Yu Y; Tian P; Li Z
Diabetes Obes Metab; 2024 Mar; 26(3):1040-1049. PubMed ID: 38086546
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.
Guo M; Ding J; Li J; Wang J; Zhang T; Liu C; Huang W; Long Y; Gao C; Xu Y
Diabetes Obes Metab; 2018 Aug; 20(8):1977-1982. PubMed ID: 29573118
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Li D; Wu T; Wang T; Wei H; Wang A; Tang H; Song Y
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):582-590. PubMed ID: 32124527
[TBL] [Abstract][Full Text] [Related]
14. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Wang X; Zhang F; Zhang Y; Zhang J; Sheng Y; Wang W; Li Y
Osteoporos Int; 2023 Dec; 34(12):2013-2025. PubMed ID: 37695339
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
16. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
19. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
Cowan A; Jeyakumar N; Kang Y; Dixon SN; Garg AX; Naylor K; Weir MA; Clemens KK
Clin J Am Soc Nephrol; 2022 Jun; 17(6):835-842. PubMed ID: 35618342
[TBL] [Abstract][Full Text] [Related]
20. Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.
Banerjee M; Pal R; Maisnam I; Chowdhury S; Mukhopadhyay S
Diabetes Obes Metab; 2023 Sep; 25(9):2697-2703. PubMed ID: 37334516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
